Congenital disorder of glycosylation caused by starting site-specific variant in syntaxin-5
View ORCID ProfilePeter T.A. Linders, Eveline C.F. Gerretsen, View ORCID ProfileAngel Ashikov, View ORCID ProfileMari-Anne Vals, View ORCID ProfileNatalia H. Revelo, Richard Arts, View ORCID ProfileMelissa Baerenfaenger, Fokje Zijlstra, Karin Huijben, Kimiyo Raymond, Kai Muru, Olga Fjodorova, View ORCID ProfileSander Pajusalu, View ORCID ProfileKatrin Õunap, Martin ter Beest, View ORCID ProfileDirk Lefeber, View ORCID ProfileGeert van den Bogaart
doi: https://doi.org/10.1101/2020.03.30.20044438
Peter T.A. Linders
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Eveline C.F. Gerretsen
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Angel Ashikov
2Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
3Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
Mari-Anne Vals
4Children’s Clinic, Tartu University Hospital, Estonia
5Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Estonia
Natalia H. Revelo
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Richard Arts
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Melissa Baerenfaenger
2Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
Fokje Zijlstra
3Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
Karin Huijben
3Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
Kimiyo Raymond
6Department of Laboratory Medicine and Pathology, Mayo College of Medicine, Rochester, Minnesota, USA
Kai Muru
5Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Estonia
7Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
Olga Fjodorova
7Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
Sander Pajusalu
5Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Estonia
7Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
Katrin Õunap
5Department of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Estonia
7Department of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia
Martin ter Beest
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
Dirk Lefeber
2Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
3Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
Geert van den Bogaart
1Department of Tumor Immunology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
8Department of Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, 9747AG, Groningen, Netherlands
Posted March 31, 2020.
Congenital disorder of glycosylation caused by starting site-specific variant in syntaxin-5
Peter T.A. Linders, Eveline C.F. Gerretsen, Angel Ashikov, Mari-Anne Vals, Natalia H. Revelo, Richard Arts, Melissa Baerenfaenger, Fokje Zijlstra, Karin Huijben, Kimiyo Raymond, Kai Muru, Olga Fjodorova, Sander Pajusalu, Katrin Õunap, Martin ter Beest, Dirk Lefeber, Geert van den Bogaart
medRxiv 2020.03.30.20044438; doi: https://doi.org/10.1101/2020.03.30.20044438
Congenital disorder of glycosylation caused by starting site-specific variant in syntaxin-5
Peter T.A. Linders, Eveline C.F. Gerretsen, Angel Ashikov, Mari-Anne Vals, Natalia H. Revelo, Richard Arts, Melissa Baerenfaenger, Fokje Zijlstra, Karin Huijben, Kimiyo Raymond, Kai Muru, Olga Fjodorova, Sander Pajusalu, Katrin Õunap, Martin ter Beest, Dirk Lefeber, Geert van den Bogaart
medRxiv 2020.03.30.20044438; doi: https://doi.org/10.1101/2020.03.30.20044438
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (678)
- Anesthesia (182)
- Cardiovascular Medicine (2678)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12310)
- Forensic Medicine (10)
- Gastroenterology (769)
- Genetic and Genomic Medicine (4156)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2693)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3931)
- Nursing (212)
- Nutrition (584)
- Oncology (2070)
- Ophthalmology (595)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1130)
- Primary Care Research (461)
- Public and Global Health (6576)
- Radiology and Imaging (1420)
- Respiratory Medicine (876)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)